首頁 > 市場調查報告書 > 製藥

生物標記

市場調查報告書

商品編碼

1540897

2024-2032 年按測試類型、適應症、產品、技術（聚合酶鍊式反應、下一代定序、免疫分析等）、應用和地區分類的生物標記技術市場報告

Biomarker Technologies Market Report by Test Type, Indication, Product, Technology (Polymerase Chain Reaction, Next Generation Sequencing, Immunoassay, and Others), Application, and Region 2024-2032

出版日期: 2024年08月10日 | 出版商:

IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

IMARC Group年，全球生物標記技術市場規模達到402億美元。在醫療保健、製藥和診斷領域的應用不斷增加，加上對精準醫學和疾病檢測的日益關注以及對非侵入性診斷方法的需求不斷成長的推動下，該市場正在經歷穩定成長。

生物標記技術市場分析：

市場成長與規模：在醫療保健、製藥和診斷領域不斷增加的應用的推動下，該市場目前正在穩定成長。此外，生物標記技術與研發 (R&D) 流程的整合進一步推動了這種穩定成長，增強了其在推動醫療保健、製藥和診斷方面的關鍵作用。

對非侵入性診斷方法的需求不斷成長：市場見證了對非侵入性診斷方法的需求不斷增加，這是由於其患者友善性、準確性和無需侵入性程序即可檢測疾病的有效性。

產業應用：市場正經歷醫療保健、製藥和診斷等不同行業的高需求，凸顯了它們的多功能性和廣泛採用。

地理趨勢：北美由於其強大的基礎設施、對研發的大量投資以及對醫療保健創新的高度重視，在生物標記技術市場上處於領先地位。

競爭格局：市場的特點是競爭激烈，主要參與者專注於創新和擴大市場佔有率，導致生物標記技術不斷進步。

挑戰與機會：雖然監管障礙帶來了挑戰，但它也帶來了個人化醫療和診斷突破，為產業參與者提供了令人興奮的機會。

未來展望：生物標記技術市場的未來看起來充滿希望，特別是在個人化醫療和增強疾病檢測領域。

生物標記技術市場趨勢：

精準醫療需求不斷成長

對精準醫療不斷成長的需求是生物標記技術市場的主要驅動力。精準醫學代表了醫療保健領域的典範轉移，旨在根據患者獨特的遺傳、分子和臨床特徵為其提供個人化治療策略。生物標記在這一轉變中發揮關鍵作用。它們是反映體內各種生物過程的可測量指標。在精準醫學的背景下，它們是識別特定疾病亞型、預測疾病進展和確定最有效治療方法的重要工具。透過分析生物標記，醫療保健專業人員可以針對個別患者量身定做干涉措施，最佳化治療結果，同時最大限度地減少潛在的副作用。精準醫學最引人注目的方面之一是它徹底改變癌症治療的潛力。生物標記技術使腫瘤學家能夠識別腫瘤中的基因突變和蛋白質標記，從而能夠選擇專門針對癌症潛在分子促進因素的標靶療法。這增加了成功治療的機會，減少了反覆試驗的需要，使患者免受無效治療和不必要的毒性的影響，從而推動市場成長。

組學技術的進步

組學技術的進步是生物標記技術市場的另一個重要驅動力。組學涵蓋各種科學學科，包括基因組學、蛋白質組學和代謝組學，每個學科在生物標記的發現和開發中都發揮著至關重要的作用。基因組學涉及對個體完整 DNA 集的研究，提供與疾病相關的遺傳變異和突變的見解。 DNA 定序技術的不斷進步使得基因組分析變得更快、更具成本效益，從而識別出與各種狀況相關的眾多遺傳生物標記。如此豐富的基因組資料擴大了個人化醫療和標靶治療開發的潛力。蛋白質體學專注於生物系統內蛋白質的研究。質譜分析和其他創新的蛋白質體學技術使研究人員能夠識別與疾病或治療反應相關的特定蛋白質生物標記。這些生物標記對於改善疾病診斷、監測和藥物開發具有巨大的前景。代謝組學檢查生物樣本中的小分子和代謝物，揭示代謝途徑和失調。因此，組學技術的進步不斷豐富生物標記工具箱，促進新生物標記的發現，增強我們對疾病的理解，並推動診斷和藥物開發的創新。

慢性病負擔增加

慢性病負擔不斷增加是推動生物標記技術市場成長的重要因素。心血管疾病、糖尿病、癌症和呼吸系統疾病等慢性疾病是日益嚴重的全球健康挑戰。人口老化、生活方式的改變和環境因素等因素導致這些疾病的盛行率不斷增加。生物標記技術已成為對抗慢性病的關鍵工具。它們提供了早期準確檢測的潛力，這對於有效的疾病管理和改善患者的治療效果至關重要。生物標記可以識別身體的細微變化，這些變化可能表明慢性疾病的發作或進展，通常在臨床症狀出現之前。這種早期檢測使醫療保健專業人員能夠及時介入、實施個人化治療計劃並更密切地監測疾病進展。隨著全球慢性病負擔持續增加，對支持早期檢測、精確監測和個人化治療策略的生物標記技術的需求不斷增加。

市場結構
關鍵參與者
關鍵參與者簡介
- Agilent Technologies Inc.
- Bio-Rad Laboratories Inc.
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Illumina Inc.
- LI-COR Inc.
- Merck KGaA
- PerkinElmer Inc.
- QIAGEN NV
- Shimadzu Corporation
- Thermo Fisher Scientific Inc.
- Waters Corporation

簡介目錄圖表

Product Code: SR112024A4341

The global biomarker technologies market size reached US$ 40.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 113.4 Billion by 2032, exhibiting a growth rate (CAGR) of 11.8% during 2024-2032. The market is experiencing steady growth, driven by increasing applications in healthcare, pharmaceuticals, and diagnostics, coupled with a heightening focus on precision medicine and disease detection and the rising demand for non-invasive diagnostic methods.

Biomarker Technologies Market Analysis:

Market Growth and Size: The market is currently witnessing stable growth, fueled by its increasing applications in healthcare, pharmaceuticals, and diagnostics. Additionally, the integration of biomarker technologies into research and development (R&D) processes further fuels this stable growth, enhancing their pivotal role in advancing healthcare, pharmaceuticals, and diagnostics.

Rising Demand for Non-Invasive Diagnostic Methods: The market witnesses an increasing demand for non-invasive diagnostic methods, driven by their patient-friendly nature, accuracy, and effectiveness in detecting diseases without the need for invasive procedures.

Industry Applications: The market is experiencing high demand from diverse industries, including healthcare, pharmaceuticals, and diagnostics, highlighting their versatility and widespread adoption.

Geographical Trends: North America leads the biomarker technologies market due to its robust infrastructure, significant investments in research and development, and a strong focus on healthcare innovation.

Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation and expanding their market share, resulting in continuous advancements in biomarker technology.

Challenges and Opportunities: While regulatory hurdles present challenges, it also promises of personalized medicine and diagnostic breakthroughs that offers exciting opportunities for industry players.

Future Outlook: The future of the biomarker technologies market looks promising, especially in the realms of personalized medicine and enhanced disease detection.

Biomarker Technologies Market Trends:

Growing demand for precision medicine

The growing demand for precision medicine is a maior driving force in the biomarker technologies market. Precision medicine represents a paradigm shift in healthcare, aiming to provide personalized treatment strategies for patients based on their unique genetic, molecular, and clinical characteristics. Biomarkers play a pivotal role in this transformation. They are measurable indicators that reflect various biological processes within the body. In the context of precision medicine, they serve as crucial tools for identifying specific disease subtypes, predicting disease progression, and determining the most effective treatment approaches. By analyzing biomarkers, healthcare professionals can tailor interventions to individual patients, optimizing therapeutic outcomes while minimizing potential side effects. One of the most compelling aspects of precision medicine is its potential to revolutionize cancer care. Biomarker technologies allow oncologists to identify genetic mutations and protein markers in tumors, enabling the selection of targeted therapies that specifically address the underlying molecular drivers of cancer. This increases the chances of successful treatment and reduces the need for trial-and-error approaches, sparing patients from ineffective therapies and unnecessary toxicity, thereby fueling market growth.

Advancements in omics technologies

Advancements in omics technologies represent another significant driver in the biomarker technologies market. Omics encompasses various scientific disciplines, including genomics, proteomics, and metabolomics, each of which plays a crucial role in biomarker discovery and development. Genomics involves the study of an individual's complete set of DNA, providing insights into genetic variations and mutations associated with diseases. Ongoing advancements in DNA sequencing technologies have made it faster and more cost-effective to analyze the genome, leading to the identification of numerous genetic biomarkers linked to various conditions. This wealth of genomic data expands the potential for personalized medicine and the development of targeted therapies. Proteomics focuses on the study of proteins within biological systems. Mass spectrometry and other innovative proteomic techniques enable researchers to identify specific protein biomarkers associated with diseases or treatment responses. These biomarkers hold immense promise for improving disease diagnosis, monitoring, and drug development. Metabolomics examines the small molecules and metabolites in biological samples, shedding light on metabolic pathways and dysregulations. As a result, advancements in omics technologies continue to enrich the biomarker toolbox, facilitating the discovery of new biomarkers, enhancing our understanding of diseases, and driving innovation in diagnostics and drug development.

Increasing burden of chronic diseases

The escalating burden of chronic diseases is a significant factor propelling the growth of the biomarker technologies market. Chronic diseases, such as cardiovascular diseases, diabetes, cancer, and respiratory disorders, are a growing global health challenge. Factors like aging populations, lifestyle changes, and environmental factors contribute to the increasing prevalence of these conditions. Biomarker technologies have emerged as critical tools in the battle against chronic diseases. They offer the potential for early and accurate detection, which is crucial for effective disease management and improved patient outcomes. Biomarkers can identify subtle changes in the body that may indicate the onset or progression of a chronic disease, often before clinical symptoms manifest. This early detection empowers healthcare professionals to intervene promptly, implement personalized treatment plans, and monitor disease progression more closely. As the burden of chronic diseases continues to rise globally, there has been a heightened demand for biomarker technologies that support early detection, precise monitoring, and personalized treatment strategies.

Biomarker Technologies Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on indication, product, technology and application.

Breakup by Test Type:

Solid Biopsy

Liquid Biopsy

Liquid biopsy accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the test type. This includes solid biopsy and liquid biopsy. According to the report, liquid biopsy represented the largest segment.

Liquid biopsy has emerged as a transformative force in the biomarker technologies market. This non-invasive method involves analyzing biomarkers present in bodily fluids, such as blood or urine, to detect diseases, particularly cancer. Liquid biopsies offer numerous advantages, including early disease detection, real-time monitoring, and the ability to track treatment response. They reduce the need for invasive procedures and provide valuable information on tumor heterogeneity. As the demand for less invasive and more accessible diagnostic methods increases, liquid biopsies are driving the market further by expanding applications beyond traditional tissue-based biopsies and revolutionizing the field of diagnostics. Their potential to improve patient care and outcomes makes them a key market driver.

Solid biopsy methods involve the extraction of tissue samples from tumors or other abnormal growths for analysis. Solid biopsies provide essential biomarker data that guide treatment decisions, especially in cancer care. They also enable the identification of specific genetic, protein, or molecular markers, aiding in the selection of targeted therapies and predicting treatment responses. As precision medicine gains prominence, solid biopsy-derived biomarkers become indispensable, contributing to the market growth. Advancements in solid biopsy techniques, such as minimally invasive procedures, improve patient comfort and further fuel their adoption rate.

Breakup by Indication:

Cancer

Infectious Diseases

Autoimmune Disorders

Cardiovascular Disorders

Others

Cancer holds the largest share in the industry

A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and others. According to the report, cancer accounted for the largest market share.

Biomarker technologies are instrumental in the fight against cancer, providing essential tools for early detection, precise diagnosis, and tailored treatment strategies. They enable the identification of specific genetic and molecular markers, improving patient outcomes and driving substantial market growth in the oncology sector. They also play a crucial role in infectious disease management by facilitating rapid and accurate pathogen detection, monitoring treatment responses, and aiding in epidemiological studies, contributing significantly to the market's expansion, particularly in the context of global health crises.

Biomarker technologies are pivotal in diagnosing and monitoring autoimmune disorders, offering insights into disease progression and treatment efficacy, thus driving their adoption and furthering research in autoimmune disease management.

Biomarkers are indispensable in assessing cardiovascular health and risk factors. Their use in early diagnosis, monitoring, and personalized treatment plans fuels the demand for biomarker technologies, leading to advancements in cardiovascular care and fostering market growth.

Breakup by Product:

Consumables

Assay

Reagent

Instruments

Consumables represent the leading market segment

The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables, assay, reagent, and instruments. According to the report, consumables represented the largest segment.

Consumables, including sample collection kits and containers, are vital components of biomarker technology workflows. They are essential for collecting and preserving biological samples, making them indispensable for research, diagnostics, and drug development. The steady demand for these consumables ensures a consistent revenue stream in the biomarker technologies market.

Assays are at the heart of biomarker analysis. They encompass a wide range of techniques, such as ELISA and PCR, used to detect and quantify specific biomarkers. The development of innovative assay methods and kits further catalyzed market growth as they enable more precise and efficient biomarker detection.

Reagents are essential chemical compounds used in various stages of biomarker analysis. They play a critical role in sample preparation, labeling, and detection. The continuous need for high-quality reagents, especially for emerging biomarkers, fuels market demand, making reagents a lucrative segment.

Biomarker detection instruments, such as mass spectrometers and PCR machines, are the technological backbone of biomarker analysis. Advances in instrument capabilities, including sensitivity and throughput, significantly impact market growth. As research and diagnostic needs evolve, there has been a rise in the demand for cutting-edge biomarker detection instruments.

Breakup by Technology:

Polymerase Chain Reaction (PCR)

Next Generation Sequencing (NGS)

Immunoassay

Others

Immunoassay accounts for the majority of market share

The report has provided a detailed breakup and analysis of the market based on the technology. This includes polymerase chain reaction (PCR), next generation sequencing (NGS), immunoassay, and others. According to the report, immunoassay represented the largest segment.

Immunoassays are key for detecting protein biomarkers. They offer specificity, making them crucial in clinical diagnostics and research. Constant innovation in immunoassay platforms and reagents continues to propel the biomarker technologies market forward, enhancing biomarker detection sensitivity and precision.

Polymerase Chain Reaction (PCR) technology revolutionized biomarker analysis by enabling the amplification of DNA sequences. It plays a pivotal role in identifying genetic biomarkers, offering high specificity and sensitivity. Its versatility in applications, from disease diagnostics to gene expression analysis, ensures its enduring importance in the biomarker technologies market.

Next Generation Sequencing (NGS) technology enables comprehensive genomic and transcriptomic analysis. It contributes to biomarker discovery by identifying genetic variations associated with diseases. Its ability to process large datasets rapidly has accelerated research, making NGS a major driving force in biomarker-related advancements.

Breakup by Application:

Drug Discovery

Clinical Diagnostics

Personalized Medicine

Drug discovery represents the leading market segment

The report has provided a detailed breakup and analysis of the market based on the application. This includes drug discovery, clinical diagnostics, and personalized medicine. According to the report, drug discovery represented the largest segment.

Biomarker technologies are indispensable in drug discovery, aiding in target identification, validation, and efficacy assessment. They streamline the drug development process by identifying potential therapeutic targets and predicting drug responses, reducing costs and accelerating time to market.

In clinical diagnostics, biomarkers play a pivotal role in disease diagnosis, prognosis, and treatment monitoring. Their use enhances healthcare by enabling early disease detection and personalized treatment plans, spurring the adoption of biomarker technologies in clinical settings, ultimately improving patient outcomes.

Biomarker technologies are the cornerstone of personalized medicine, allowing healthcare providers to tailor treatments based on individual patient profiles. This approach improves treatment efficacy, reduces adverse effects, and fosters patient-centric healthcare, thus fueling the growth of biomarker technologies in personalized medicine applications, revolutionizing healthcare delivery.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America leads the market, accounting for the largest biomarker technologies market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest market share since the region boasts a robust infrastructure, significant R&D investments, and a focus on healthcare innovation. The region's commitment to cutting-edge research and clinical applications positions it as a key driver of biomarker technology advancement.

Asia Pacific is also an expanding market for biomarker technologies owing to increasing healthcare investments, growing research capabilities, and a rising burden of chronic diseases. The region's emphasis on precision medicine and personalized healthcare drives demand for biomarker-based diagnostics and treatment strategies.

Europe's biomarker technologies market benefits from strong collaborations between academia and industry. It thrives on the continent's commitment to healthcare innovation, making it a prominent player in biomarker research and application development.

Biomarker technologies are rapidly gaining traction in the Middle East and Africa, supported by a growing demand for improved healthcare solutions. The region's increasing healthcare expenditure and heightened focus on disease prevention contribute to the adoption of biomarker-based diagnostics.

Latin America exhibits a growing biomarker technologies market, fueled by the rising prevalence of chronic diseases and a growing awareness of personalized medicine. The region's expanding healthcare infrastructure and research initiatives are driving the demand for biomarker-based solutions, making it a notable contributor to market growth.

Leading Key Players in the Biomarker Technologies Industry:

Various key players in the market are actively engaging innovation and strategic partnerships to maintain their competitive edge. They are also investing in research and development to enhance the sensitivity and specificity of biomarker detection methods. Additionally, these companies are expanding their product portfolios to cover a broader range of biomarkers and applications, catering to the growing demand for personalized medicine. Collaborations with academic institutions and pharmaceutical companies are common, fostering the discovery and validation of novel biomarkers. Moreover, these market leaders are focused on complying with regulatory standards to ensure the safety and effectiveness of their biomarker-based products, ultimately shaping the future of diagnostics and treatment in healthcare.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

Agilent Technologies Inc.

Bio-Rad Laboratories Inc.

Danaher Corporation

F. Hoffmann-La Roche AG

Illumina Inc.

LI-COR Inc.

Merck KGaA

PerkinElmer Inc.

QIAGEN N.V.

Shimadzu Corporation

Thermo Fisher Scientific Inc.

Waters Corporation

(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)

Latest News:

August 30, 2022: Thermo Fisher Scientific, Inc. launched CE-IVD (IVDD) NGS test and analysis software to expand access to personalized oncology biomarker testing. This announcement underscores the company's commitment to advancing the accessibility and accuracy of molecular diagnostics for cancer patients. The CE-IVD certification is a crucial regulatory milestone, indicating that the NGS test and associated software meet the rigorous standards required for diagnostic use in Europe. This certification ensures the reliability and consistency of the test results, making them suitable for clinical decision-making.

December 4, 2023: Agilent Technologies Inc. announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features improve image quality and results by reducing deleterious effects on live-cell samples and enhancing clarity for thicker samples such as tissues and 3-D spheroids. Agilent Technologies Inc.'s enhancement of the BioTek Cytation C10 confocal imaging reader underscores their commitment to providing cutting-edge solutions for live-cell imaging and advancing research in 3-D biological models.

November 22, 2023: Danaher Corporation's development of a comprehensive mRNA production ecosystem strengthens its position as a leading provider of integrated solutions for the biotechnology and pharmaceutical industries, facilitating the efficient production of mRNA therapeutics at various scales.

Key Questions Answered in This Report:

How has the global biomarker technologies market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global biomarker technologies market?
What is the impact of each driver, restraint, and opportunity on the global biomarker technologies market?
What are the key regional markets?
Which countries represent the most attractive biomarker technologies market?
What is the breakup of the market based on the test type?
Which is the most attractive test type in the biomarker technologies market?
What is the breakup of the market based on the indication?
Which is the most attractive indication in the biomarker technologies market?
What is the breakup of the market based on the product?
Which is the most attractive product in the biomarker technologies market?
What is the breakup of the market based on technology?
Which is the most attractive technology in the biomarker technologies market?
What is the breakup of the market based on the application?
Which is the most attractive application in the biomarker technologies market?
What is the competitive structure of the market?
Who are the key players/companies in the global biomarker technologies market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Biomarker Technologies Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Test Type

6.1 Solid Biopsy
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Liquid Biopsy
- 6.2.1 Market Trends
- 6.2.2 Market Forecast

7 Market Breakup by Indication

7.1 Cancer
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Infectious Diseases
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Autoimmune Disorders
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Cardiovascular Disorders
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by Product

8.1 Consumables
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Assay
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Reagent
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Instruments
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Technology

9.1 Polymerase Chain Reaction (PCR)
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Next Generation Sequencing (NGS)
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Immunoassay
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast

10 Market Breakup by Application

10.1 Drug Discovery
- 10.1.1 Market Trends
- 10.1.2 Market Forecast
10.2 Clinical Diagnostics
- 10.2.1 Market Trends
- 10.2.2 Market Forecast
10.3 Personalized Medicine
- 10.3.1 Market Trends
- 10.3.2 Market Forecast

11 Market Breakup by Region

11.1 North America
- 11.1.1 United States
  - 11.1.1.1 Market Trends
  - 11.1.1.2 Market Forecast
- 11.1.2 Canada
  - 11.1.2.1 Market Trends
  - 11.1.2.2 Market Forecast
11.2 Asia-Pacific
- 11.2.1 China
  - 11.2.1.1 Market Trends
  - 11.2.1.2 Market Forecast
- 11.2.2 Japan
  - 11.2.2.1 Market Trends
  - 11.2.2.2 Market Forecast
- 11.2.3 India
  - 11.2.3.1 Market Trends
  - 11.2.3.2 Market Forecast
- 11.2.4 South Korea
  - 11.2.4.1 Market Trends
  - 11.2.4.2 Market Forecast
- 11.2.5 Australia
  - 11.2.5.1 Market Trends
  - 11.2.5.2 Market Forecast
- 11.2.6 Indonesia
  - 11.2.6.1 Market Trends
  - 11.2.6.2 Market Forecast
- 11.2.7 Others
  - 11.2.7.1 Market Trends
  - 11.2.7.2 Market Forecast
11.3 Europe
- 11.3.1 Germany
  - 11.3.1.1 Market Trends
  - 11.3.1.2 Market Forecast
- 11.3.2 France
  - 11.3.2.1 Market Trends
  - 11.3.2.2 Market Forecast
- 11.3.3 United Kingdom
  - 11.3.3.1 Market Trends
  - 11.3.3.2 Market Forecast
- 11.3.4 Italy
  - 11.3.4.1 Market Trends
  - 11.3.4.2 Market Forecast
- 11.3.5 Spain
  - 11.3.5.1 Market Trends
  - 11.3.5.2 Market Forecast
- 11.3.6 Russia
  - 11.3.6.1 Market Trends
  - 11.3.6.2 Market Forecast
- 11.3.7 Others
  - 11.3.7.1 Market Trends
  - 11.3.7.2 Market Forecast
11.4 Latin America
- 11.4.1 Brazil
  - 11.4.1.1 Market Trends
  - 11.4.1.2 Market Forecast
- 11.4.2 Mexico
  - 11.4.2.1 Market Trends
  - 11.4.2.2 Market Forecast
- 11.4.3 Others
  - 11.4.3.1 Market Trends
  - 11.4.3.2 Market Forecast
11.5 Middle East and Africa
- 11.5.1 Market Trends
- 11.5.2 Market Breakup by Country
- 11.5.3 Market Forecast

12 SWOT Analysis

12.1 Overview
12.2 Strengths
12.3 Weaknesses
12.4 Opportunities
12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

14.1 Overview
14.2 Bargaining Power of Buyers
14.3 Bargaining Power of Suppliers
14.4 Degree of Competition
14.5 Threat of New Entrants
14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

16.1 Market Structure
16.2 Key Players
16.3 Profiles of Key Players
- 16.3.1 Agilent Technologies Inc.
  - 16.3.1.1 Company Overview
  - 16.3.1.2 Product Portfolio
  - 16.3.1.3 Financials
  - 16.3.1.4 SWOT Analysis
- 16.3.2 Bio-Rad Laboratories Inc.
  - 16.3.2.1 Company Overview
  - 16.3.2.2 Product Portfolio
  - 16.3.2.3 Financials
  - 16.3.2.4 SWOT Analysis
- 16.3.3 Danaher Corporation
  - 16.3.3.1 Company Overview
  - 16.3.3.2 Product Portfolio
  - 16.3.3.3 Financials
  - 16.3.3.4 SWOT Analysis
- 16.3.4 F. Hoffmann-La Roche AG
  - 16.3.4.1 Company Overview
  - 16.3.4.2 Product Portfolio
  - 16.3.4.3 Financials
- 16.3.5 Illumina Inc.
  - 16.3.5.1 Company Overview
  - 16.3.5.2 Product Portfolio
  - 16.3.5.3 Financials
  - 16.3.5.4 SWOT Analysis
- 16.3.6 LI-COR Inc.
  - 16.3.6.1 Company Overview
  - 16.3.6.2 Product Portfolio
- 16.3.7 Merck KGaA
  - 16.3.7.1 Company Overview
  - 16.3.7.2 Product Portfolio
  - 16.3.7.3 Financials
  - 16.3.7.4 SWOT Analysis
- 16.3.8 PerkinElmer Inc.
  - 16.3.8.1 Company Overview
  - 16.3.8.2 Product Portfolio
  - 16.3.8.3 Financials
  - 16.3.8.4 SWOT Analysis
- 16.3.9 QIAGEN N.V.
  - 16.3.9.1 Company Overview
  - 16.3.9.2 Product Portfolio
  - 16.3.9.3 Financials
  - 16.3.9.4 SWOT Analysis
- 16.3.10 Shimadzu Corporation
  - 16.3.10.1 Company Overview
  - 16.3.10.2 Product Portfolio
  - 16.3.10.3 Financials
  - 16.3.10.4 SWOT Analysis
- 16.3.11 Thermo Fisher Scientific Inc.
  - 16.3.11.1 Company Overview
  - 16.3.11.2 Product Portfolio
  - 16.3.11.3 Financials
  - 16.3.11.4 SWOT Analysis
- 16.3.12 Waters Corporation
  - 16.3.12.1 Company Overview
  - 16.3.12.2 Product Portfolio
  - 16.3.12.3 Financials
  - 16.3.12.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Biomarker Technologies Market: Major Drivers and Challenges
Figure 2: Global: Biomarker Technologies Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Biomarker Technologies Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Biomarker Technologies Market: Breakup by Test Type (in %), 2023
Figure 5: Global: Biomarker Technologies Market: Breakup by Indication (in %), 2023
Figure 6: Global: Biomarker Technologies Market: Breakup by Product (in %), 2023
Figure 7: Global: Biomarker Technologies Market: Breakup by Technology (in %), 2023
Figure 8: Global: Biomarker Technologies Market: Breakup by Application (in %), 2023
Figure 9: Global: Biomarker Technologies Market: Breakup by Region (in %), 2023
Figure 10: Global: Biomarker Technologies (Solid Biopsy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Biomarker Technologies (Solid Biopsy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Biomarker Technologies (Liquid Biopsy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Biomarker Technologies (Liquid Biopsy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Biomarker Technologies (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Biomarker Technologies (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Biomarker Technologies (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Biomarker Technologies (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Biomarker Technologies (Autoimmune Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Biomarker Technologies (Autoimmune Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Biomarker Technologies (Cardiovascular Disorders) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Biomarker Technologies (Cardiovascular Disorders) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Biomarker Technologies (Other Indications) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Biomarker Technologies (Other Indications) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Biomarker Technologies (Consumables) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Biomarker Technologies (Consumables) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Biomarker Technologies (Assay) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Biomarker Technologies (Assay) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Biomarker Technologies (Reagent) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Biomarker Technologies (Reagent) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Biomarker Technologies (Instruments) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Biomarker Technologies (Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: Global: Biomarker Technologies (Polymerase Chain Reaction - PCR) Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: Global: Biomarker Technologies (Polymerase Chain Reaction - PCR) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Global: Biomarker Technologies (Next Generation Sequencing - NGS) Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Global: Biomarker Technologies (Next Generation Sequencing - NGS) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Global: Biomarker Technologies (Immunoassay) Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Global: Biomarker Technologies (Immunoassay) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Global: Biomarker Technologies (Other Technologies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Global: Biomarker Technologies (Other Technologies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Global: Biomarker Technologies (Drug Discovery) Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Global: Biomarker Technologies (Drug Discovery) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Global: Biomarker Technologies (Clinical Diagnostics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Global: Biomarker Technologies (Clinical Diagnostics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: Global: Biomarker Technologies (Personalized Medicine) Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: Global: Biomarker Technologies (Personalized Medicine) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: North America: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: North America: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: United States: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: United States: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Canada: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Canada: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Asia-Pacific: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Asia-Pacific: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: China: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: China: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Japan: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Japan: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: India: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: India: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: South Korea: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: South Korea: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Australia: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Australia: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Indonesia: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Indonesia: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Others: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Others: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Europe: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Europe: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Germany: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Germany: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: France: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: France: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: United Kingdom: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: United Kingdom: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Italy: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Italy: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Spain: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Spain: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 80: Russia: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 81: Russia: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 82: Others: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 83: Others: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 84: Latin America: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 85: Latin America: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 86: Brazil: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 87: Brazil: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 88: Mexico: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 89: Mexico: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 90: Others: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 91: Others: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 92: Middle East and Africa: Biomarker Technologies Market: Sales Value (in Million US$), 2018 & 2023
Figure 93: Middle East and Africa: Biomarker Technologies Market: Breakup by Country (in %), 2023
Figure 94: Middle East and Africa: Biomarker Technologies Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 95: Global: Biomarker Technologies Industry: SWOT Analysis
Figure 96: Global: Biomarker Technologies Industry: Value Chain Analysis
Figure 97: Global: Biomarker Technologies Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Biomarker Technologies Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Biomarker Technologies Market Forecast: Breakup by Test Type (in Million US$), 2024-2032
Table 3: Global: Biomarker Technologies Market Forecast: Breakup by Indication (in Million US$), 2024-2032
Table 4: Global: Biomarker Technologies Market Forecast: Breakup by Product (in Million US$), 2024-2032
Table 5: Global: Biomarker Technologies Market Forecast: Breakup by Technology (in Million US$), 2024-2032
Table 6: Global: Biomarker Technologies Market Forecast: Breakup by Application (in Million US$), 2024-2032
Table 7: Global: Biomarker Technologies Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 8: Global: Biomarker Technologies Market: Competitive Structure
Table 9: Global: Biomarker Technologies Market: Key Players

02-2729-4219

+886-2-2729-4219